Drug
Pregabalin
Pregabalin: highest development phase Post-Market, developed by Krka, Lupin, Pfizer. 11 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Krka, Lupin, Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| pregabalin NCT01020526 | Post-Market | Fibromyalgia |
| Pregabalin NCT04246619 | Post-Market | Painful Diabetic Peripheral Neuropathy |
| PREGABALIN | Approved | |
| pregabalin (Lyrica) NCT00468845 | Phase 3 | Pain, Postoperative |
| pregabalin NCT00264875 | Phase 3 | Peripheral Neuropathy |
| Pregabalin NCT00151528 | Phase 3 | Fibromyalgia |
| pregabalin NCT00537238 | Phase 3 | Partial Seizures |
| Pregabalin NCT00883740 | Phase 3 | Fibromyalgia |
| pregabalin NCT00596466 | Phase 3 | Epilepsy |
| pregabalin NCT00413010 | Phase 3 | Generalized Anxiety Disorder |
| Pregabalin ER NCT02725112 | Phase 1 | Healthy |
Latest
No recent events.
Follow Pregabalin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.